Compare DigitalOcean Holdings Inc (DOCN) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Illumina, Inc. — how do they compare? DigitalOcean Holdings Inc trades at $125.66 (market cap $14.97B), while Illumina, Inc. trades at $265 (market cap $40.43B). The key difference: Illumina, Inc. is far larger — about 2.7× DigitalOcean Holdings Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, DigitalOcean Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and Illumina, Inc. for 83 Days on average.
| DOCN | ILMN | |
|---|---|---|
Market Cap | $14.97B | $40.43B |
Volume | 1,385,194 | 2,948,626 |
Sector | Technology | Health |
52-Week High | $181.29 | $293.69 |
52-Week Low | $37.30 | $91.00 |
Typical Hold Time | 43 Days | 83 Days |
Enterprise Value | $15.73B | $41.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean trades at $123.90, down 5.47% today, but maintains strong fundamental momentum with 29% revenue growth in Q2 2026 and consistent earnings beats. The company shows robust profitability with 57.2% gross margins and 23.3% net income margins, though valuation multiples remain elevated with a P/E of 57.9. Recent product launches including Agent Droplets and a $725 million equipment financing facility support continued AI-driven growth. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, creating a consolidation pattern near key support at $122.
DigitalOcean presents a compelling growth story with strong AI adoption tailwinds, trading 28% below analyst consensus target of $172.73. The primary investment thesis hinges on continued execution of AI-native cloud strategy, though risks include high valuation multiples, negative shareholder equity, and competitive pressure from larger cloud providers. Institutional ownership trends remain positive with recent acquisitions by Bank of America and California State Teachers Retirement System.
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
